XLV Stock Recent News
XLV LATEST HEADLINES
Launched on 12/16/1998, the Health Care Select Sector SPDR ETF (XLV) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Broad segment of the equity market.
Carl Rizzuto, Versant Ventures managing director, joins 'Fast Money' to talk the impact of tariffs on healthcare.
The Health Care Select Sector SPDR ETF (XLV) was up approximately 6% year-to-date as of January 29. While it is still early days, this performance is already twice as robust as the sector ETF's performance for all of 2024.
I maintain a buy rating on the Health Care sector, highlighting XLV as the second-best performing S&P 500 sector YTD with broad-based gains. Global fund managers have increased allocations to Health Care, signaling renewed optimism and a healthier sector outlook since my Q3 2024 analysis. XLV offers compelling valuation at 16.5x earnings with a PEG ratio of 1.5x, strong dividend growth, and a diversified portfolio leaning towards large-cap value.
XLV offers a rare combination of stability and growth potential through its diverse investments in the healthcare sector, justifying a buy rating. The fund's broad exposure across various healthcare sub-sectors and market capitalizations ensures low-risk concentration and a stable portfolio. Economic and demographic factors, including technological advancements and an aging population, are key growth catalysts for the healthcare sector.
Meta Platforms (META) reports earnings after the closing bell, and @Theotrade's Don Kaufman is bearish on the Mag 7 company. He thinks Meta's significant run higher could end as Don expects its report to underdeliver.
Chris Verrone, Strategas head of technical and macro research, joins 'Closing Bell' to discuss the bullish technical signs he's seeing.
These sector ETFs and stocks may win amid cooling inflation.
The JPMorgan Healthcare Conference is a place where deals happen. As the conference kicked off, deals were announced from Eli Lilly (LLY), Johnson & Johnson (JNJ), and GSK (GSK).
Total S&P 500 earnings are expected to be up 7.4% from the year-ago period on 4.8% higher revenues.